Clinical Study

High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases

Table 2

Predicted duration of survival versus actual duration of survival (by DS-GPA score).

PatientDS-GPAPredicted median duration of survival based on DS-GPA (months)Duration of survival from HD IL-2 initiation (months)Duration of survival from diagnosis of brain metastases (months)

813.383.0 4.7

124.76.7 7.4
424.713.315.2
524.718.2 19.6
624.75.3 5.4

238.7710.6 13.5
738.772.15.1

3413.219.023.7